ALBOMED GmbH

What ALBOMED GmbH does

ALBOMED GmbH is a privately-held German medical device manufacturer headquartered in Schwarzenbruck, Bavaria, with administrative offices in Burgthann and dedicated logistics and production facilities in Unna (built in 2021 and 2024 respectively). The company operates in two specialty verticals: ophthalmology and orthopaedics, in both cases focused on viscoelastic substances derived from bio-fermented sodium hyaluronate and hydroxypropyl methylcellulose. Its ophthalmology portfolio comprises Pe-Ha-Luron F (cohesive HA viscoelastic), Pe-Ha-Visco (pseudoplastic viscoelastic), and Pe-Ha-Guard (corneal wetting agent for IOL implantation), covering the cohesive, pseudoplastic, and dispersive/wetting needs of cataract and intraocular surgical workflows. The orthopaedics portfolio consists of KD Intra-Articular Gel and the 2022-launched INNORYOS, the latter pairing HA with niacinamide to deliver combined visco-supplementation and anti-inflammatory/antioxidant effect in osteoarthritis patients. Legacy products include Pe-Ha-Glide (2014) and Pe-Ha-Blue (2015, trypan-blue viscoelastic). Both product lines hold EU MDR certification (ophthalmic 2021, orthopaedic 2024), positioning ALBOMED ahead of many peers in meeting tightened EU regulatory standards.

The company generates revenue almost entirely through direct B2B sales of single-use viscoelastic syringes and gels to ophthalmologists, eye surgeons, orthopaedic surgeons, rheumatologists, and clinics that administer these products during surgical procedures or intra-articular injections. There is no disclosed pricing model, no subscription or SaaS component, and no named end-customer logos in the available data. Go-to-market is event-driven: ALBOMED maintains an active presence across 10+ international congresses annually (ESCRS, WHX Dubai, EFORT, ESSKA, APACRS, WOC, EORS, CPHI, DKOU, DOC, VSOU), supplemented by a LinkedIn corporate page and a YouTube channel for educational content. Distributor and partnership channels are not disclosed in the source material, although a 2025 humanitarian engagement in the Central African Republic suggests nascent activity in sub-Saharan markets.

The company was originally founded in 1995 as Pe-Ha-Intraocular (a BSS and viscoelastic distributor), was reorganized under ALBOMED GmbH in 1999, and has since grown from a distribution entity into an MDR-compliant in-house developer and manufacturer. It operates with approximately 20 employees, no disclosed subsidiaries, no disclosed funding rounds, no private equity or venture capital backing, and no parent company; ownership is not publicly disclosed but appears to be founder/management-held. The company reports no disclosed revenue and is not listed on any exchange. The principal growth levers visible in the data are geographic expansion (driven by international congress presence and export-readiness investments in the Unna facilities), product line extension (INNORYOS mechanism innovation), and continued regulatory progression.

Name

ALBOMED GmbH

Legal name

ALBOMED GmbH

Website

https://albomed.eu

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

ALBOMED GmbH is a privately held German manufacturer of viscoelastic medical devices for ophthalmology and orthopaedics, selling hyaluronic acid and cellulose-based syringes and gels directly to healthcare professionals and clinics worldwide.

Ownership category

akta.pro rank

Product category

Ophthalmic and Orthopaedic Viscoelastic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Ophthalmic Goods (3851), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

akta.pro secondary industry

Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

Keywords

• Viscoelastic medical devices
• Ophthalmic surgical products
• Orthopaedic hyaluronic acid
• Viscosurgical devices
• Intra-articular injections

Headquarters

HQ city

Schwarzenbruck

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Product Sales: Sale of viscoelastic medical products for ophthalmology and orthopaedics including syringes, gels, and solutions. Products include Pe-Ha-Luron®F, Pe-Ha-Visco®, Pe-Ha-Guard® for ophthalmology and KD Intra-Articular®Gel, INNORYOS® for orthopaedics. Revenue is generated through direct product sales to healthcare professionals and medical institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ALBOMED GmbH develops, manufactures, and sells viscoelastic medical devices for ophthalmology and orthopaedics. Its ophthalmology portfolio includes Pe-Ha-Luron® F (cohesive hyaluronic acid viscoelastic), Pe-Ha-Visco® (pseudoplastic viscoelastic), and Pe-Ha-Guard® (HPMC-based wetting agent) used during cataract surgery, anterior chamber maintenance, and intraocular lens implantation. Its orthopaedics portfolio includes KD Intra-Articular® Gel (sodium hyaluronate for intra-articular injection) and INNORYOS® (visco-booster combining hyaluronic acid with niacinamide for osteoarthritis treatment). Products are MDR-certified and sold directly to healthcare professionals and medical institutions worldwide.

Product overview

ALBOMED GmbH is a manufacturer of modern viscoelastics for medical applications in two core areas: Ophthalmology and Orthopaedics. The ophthalmology portfolio includes Pe-Ha-Luron® F (cohesive hyaluronic acid viscoelastic), Pe-Ha-Visco® (pseudoplastic viscoelastic), and Pe-Ha-Guard® (wetting agent for corneal epithelium and IOL implantation). The orthopaedics portfolio includes KD Intra-Articular® Gel (sodium hyaluronate for intra-articular injection) and INNORYOS® (visco-booster with hyaluronic acid and niacinamide for osteoarthritis). The company also previously produced legacy products including Pe-Ha-Luron®, Pe-Ha-Glide®, and Pe-Ha-Blue®.

Differentiator

Problem solved

Functional benefit

Brands

• Pe-Ha-Luron® F: Viscoelastic substance based on hyaluronic acid for ophthalmological procedures
• Pe-Ha-Visco®
• Pe-Ha-Guard®
• KD Intra-Articular® Gel
• INNORYOS®
• Pe-Ha-Luron®
• Pe-Ha-Glide®
• Pe-Ha-Blue®

Quantifiable outcome

• INNORYOS® 2.2% demonstrates efficacy in patients with knee osteoarthritis with best overall functional behavior for dynamic activities

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Anika Therapeutics: Specialist in hyaluronic acid-based orthopaedic therapies (Orthovisc, Monovisc, Cingal), directly comparable to ALBOMED's KD Intra-Articular® Gel and INNORYOS® viscosupplement franchise.
• Seikagaku Corporation: Japanese specialty HA manufacturer with viscosupplements (Supartz, Gel-One, HyLink) and ophthalmic HA products; comparable pure-play HA portfolio to ALBOMED.
• Bioventus: Markets viscosupplements (Supartz, Durolane, Gelsyn-3) for knee osteoarthritis, directly comparable to ALBOMED's orthopaedic intra-articular HA product line.
• TRB Chemedica: European specialist in viscoelastic and viscosupplement products (Ostenil, Viscose, Cystistat) used in ophthalmology and orthopaedics — a closely comparable European HA-based peer.

Broad incumbents

• Alcon: Global leader in ophthalmic surgery. Its Healon/DisCoVisc family of viscoelastic products directly competes with ALBOMED's Pe-Ha-Luron®F, Pe-Ha-Visco®, and Pe-Ha-Guard® in cataract and IOL procedures.
• Carl Zeiss Meditec: German-headquartered ophthalmic device major; competes across cataract surgery workflows and is a logical nearby peer for ALBOMED's ophthalmic viscoelastic business.
• Bausch + Lomb: Diversified ophthalmic company with the Amvisc/Amvisc Plus viscoelastic portfolio used in cataract surgery, directly comparable to ALBOMED's ophthalmic viscoelastic offering.
• Sanofi (Specialty Care / Synvisc franchise): Held the Synvisc/Synvisc-One viscosupplement franchise (sold to Société des Produits Nestlé/Sobi), a benchmark competitor in the HA intra-articular OA market alongside ALBOMED's KD line.
• Johnson & Johnson Vision: Sells the OcuCoat viscoelastic and bundles it with phaco and IOL systems, competing head-to-head with ALBOMED's ophthalmic viscoelastics in the surgical ophthalmology channel.

Emerging players

• Hyaluronic Acid / Santen Pharmaceutical: Japanese ophthalmic specialist with significant presence in surgical ophthalmology and HA-based products, providing an adjacent peer benchmark for ALBOMED's ophthalmic business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ALBOMED
• LinkedInlinkedin.com/company/albomed

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALBOMED GmbH